Evaluation of bone marrow morphology is essential for assessing disease status in recombinant interferon α-treated polycythemia vera patients.
Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.
Elizabeth
E
Margolskee
Richard T. Silver Center for Myeloproliferative Neoplasms, Division of Hematology/Medical Oncology, Weill Cornell Medicine, New York, NY, USA.
Spencer
S
Krichevsky
Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.
Attilio
A
Orazi
Richard T. Silver Center for Myeloproliferative Neoplasms, Division of Hematology/Medical Oncology, Weill Cornell Medicine, New York, NY, USA rtsilver@med.cornell.edu.
Richard T
RT
Silver
D001706:Biopsy; D001853:Bone Marrow / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D019468:Disease Management; D016903:Drug Monitoring; D005260:Female; D015870:Gene Expression; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D053614:Janus Kinase 2 / Q000235:genetics* / Q000378:metabolism; D008297:Male; D008533:Megakaryocytes / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D008875:Middle Aged; D009154:Mutation; D011087:Polycythemia Vera / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000627:therapeutic use; D050799:STAT5 Transcription Factor / Q000235:genetics* / Q000378:metabolism; D016896:Treatment Outcome
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D050799:STAT5 Transcription Factor; D011092:Polyethylene Glycols; C507924:JAK2 protein, human; D053614:Janus Kinase 2; C417083:peginterferon alfa-2b; C100416:peginterferon alfa-2a